



**CELOX<sup>+</sup> RAPID**  
Z-Fold Haemostatic Gauze  
One Gauze Strip 1.5m x 7.6cm

**CELOX<sup>+</sup> GRANULES**  
15g Haemostatic Granules

**CELOX<sup>+</sup> GAUZE**  
Z-Fold Haemostatic Gauze  
One Gauze Strip 1.5m x 7.6cm

**CELOX<sup>+</sup> MEDICAL**  
MADE TO SAVE LIVES



**Severe traumatic injury is a major worldwide public health issue which causes significant social and economic consequences for societies.<sup>1</sup>**

It contributes to one in every ten mortalities,<sup>2</sup> and the annual global death rate is increasing year-on-year.<sup>3</sup>

The World Health Organization recognises road traffic accidents, suicides and homicides as the three leading causes of injury and violence-related deaths,<sup>4</sup> with uncontrolled post-traumatic bleeding being a leading cause of preventable death, both in civilian life<sup>2,5</sup> and on the battlefield.<sup>6</sup>

In response, a number of national and international initiatives have sought to prevent violence- and trauma-related injuries and to also improve the management of severe bleeds in trauma patients via innovative treatment approaches, educational measures, and state-of-the-art clinical practice guidelines.<sup>7</sup>

The aim is to improve outcomes by assisting in the timely identification of bleeding sources, followed by prompt measures to stop bleeding and restore haemodynamic stability.<sup>8</sup>



# CONTENTS

## PAGE

|    |                                           |
|----|-------------------------------------------|
| 4  | Introduction: CELOX Medical               |
| 5  | CELOX Technology                          |
| 6  | How CELOX is different to Chitosan        |
| 7  | Product Indications                       |
| 8  | Clinical Summaries                        |
| 9  | Compendium: 1 2                           |
| 10 | Compendium: 3 4                           |
| 11 | Compendium: 5 6                           |
| 12 | Real World Performance - PMCF CELOX       |
| 13 | Real World Performance - PMCF CELOX       |
| 14 | Real World Performance - PMCF CELOX Rapid |
| 15 | Real World Performance - PMCF CELOX Rapid |
| 16 | Core Product Range                        |

## CELOX RAPID GAUZE

|    |                                      |
|----|--------------------------------------|
| 17 | Technical Data Sheet - CELOX Rapid   |
| 18 | How To Guide - CELOX Rapid           |
| 19 | Product Specifications - CELOX Rapid |

## CELOX GAUZE

|    |                                      |
|----|--------------------------------------|
| 20 | Technical Data Sheet - CELOX Gauze   |
| 21 | How To Guide - CELOX Gauze           |
| 22 | Product Specifications - CELOX Gauze |

## CELOX GRANULES

|    |                                         |
|----|-----------------------------------------|
| 23 | Technical Data Sheet - CELOX Granules   |
| 24 | How To Guide - CELOX Granules           |
| 25 | Product Specifications - CELOX Granules |

## CELOX APPLICATOR

|    |                                           |
|----|-------------------------------------------|
| 26 | Technical Data Sheet - CELOX Applicator   |
| 27 | How To Guide - CELOX Applicator           |
| 28 | Product Specifications - CELOX Applicator |

## FOXSEAL

|    |                                           |
|----|-------------------------------------------|
| 29 | FOXSEAL Products                          |
| 30 | Technical Data Sheet - FOXSEAL Chest seal |
| 31 | How To Guide - FOXSEAL Chest seal         |

## FOXSEAL VENTED

|    |                                                   |
|----|---------------------------------------------------|
| 32 | Technical Data Sheet - FOXSEAL Vented             |
| 33 | How To Guide - FOXSEAL Vented                     |
| 34 | Product Specifications - FOXSEAL & FOXSEAL Vented |
| 35 | References                                        |

# INTRODUCTION: CELOX MEDICAL

4

**There have been significant advances in scientific understanding and technology with respect to bleeding and haemostasis in recent years.**



Despite this, trauma remains the leading cause of human morbidity and mortality.

Traditional strategies to control bleeding with direct pressure alone may be ineffective, as may some of the haemostatic technologies which rely on activating the body's clotting cascade.

Medtrade Products Ltd, is a world-leading, independent product innovator based in the UK since 1999, and in 2006, we achieved a technological breakthrough with the launch of CELOX Granules. The technology embedded in these granules was found to save lives on the battlefield by halting life-threatening bleeding.

Since that time, we have developed five generations of our CELOX range of technologically advanced solutions in wound care, trauma wound care and surgical wound care which are key to saving lives in both military and civilian EMS scenarios.

The highly skilled experts in our medical team have a wealth of knowledge in materials science, regulatory matters, quality requirements and manufacturing processes, and use this to bring to market ground-breaking innovations that rapidly, safely, and effectively treat life-threatening bleeding in pre-hospital emergency situations.

Now used to save the lives of soldiers and civilians alike, we have continued to build our range and the latest in our brand is CELOX Rapid, the first gauze with a compression time of 60 seconds, or until bleeding stops.<sup>9</sup>

Already, it is the UK Ministry of Defence's product of choice.<sup>10</sup>



## CELOX Granules are derived from chitosan, a natural polysaccharide with a good safety profile, and proven ability to form an adherent gel clot.<sup>11</sup>

The CELOX Granules contain a high-quality activated chitosan derivative that has been innovatively developed as a haemostat and has been proven to be fast-acting, safe and highly effective in controlling life-threatening bleeding.



It is a proprietary composition which contains chitosan in the form of micro granules, high surface area, granular flakes, designed for maximum effectiveness.

The mechanism of action for CELOX Granules is through the absorption of fluid in the blood, swelling and sticking together to create a robust mechanical gel-like clot that plugs the bleeding source and seals the wound.<sup>12</sup>

This mechanism works independently of classical coagulation pathways (i.e., does not initiate a thrombogenic response).<sup>13,14</sup>

**The core material used in the CELOX formulation is Chitosan.**

5

|                          | Name                              | Source               | Diagram / illustration                                                                |
|--------------------------|-----------------------------------|----------------------|---------------------------------------------------------------------------------------|
| <b>Starting material</b> | <b>Pandalus Borealis (Shrimp)</b> | North Atlantic Ocean |  |
| <b>Intermediate</b>      | <b>Chitin</b>                     | Europe               |   |
| <b>Raw material</b>      | <b>Chitosan</b>                   | Europe               |   |
| <b>End product</b>       | <b>CELOX</b>                      | Europe               |  |



# HOW CELOX IS DIFFERENT TO CHITOSAN

**Whilst the main ingredient in CELOX is chitosan, chitosan itself is not capable of achieving the main design feature of CELOX: the potential to create haemostasis in life-threatening bleeding.**

6

| Chitosan                                                                                         | CELOX                                                       |
|--------------------------------------------------------------------------------------------------|-------------------------------------------------------------|
| Deacetylated form of chitin, a natural fibre                                                     | Is a salt form of chitosan                                  |
| Chitin is the second most abundant naturally occurring amino polysaccharide                      | Is soluble in water due to the acidic nature of the product |
| Origin and process influence chemical and physical properties                                    | High absorbency (>500% w/w)                                 |
| Chitin is insoluble in aqueous media                                                             | Forms robust viscous gel in blood and body fluids           |
| Chitosan is soluble in acidic conditions<br>→ due to protonation (NH <sub>3</sub> <sup>+</sup> ) | Exhibits mucoadhesive properties to tissue                  |
| Limited absorbency                                                                               | Protected by patented formulation                           |
| Does not form a gel in blood or body fluids                                                      | High haemostatic properties                                 |
| Limited mucoadhesion properties                                                                  |                                                             |
| Low haemostatic properties                                                                       |                                                             |

# PRODUCT INDICATIONS

## CELOX Medical product range CE

**Intended Purpose:** to be used by trained emergency responders in the pre-hospital setting for temporary treatment of emergency life-threatening bleeding.

**Patient Target Group:** adults and children, excluding neonates and infants.

Indicated for temporary external use, used to control life-threatening bleeding.



## Warning and contraindications

### Warnings and Precautions

- For external use only.
- Do not eat.
- If ingested, drink glass of water to avoid discomfort.
- Loss of sterility potentially poses a risk of infection.
- Do not resterilise.
- Avoid inhalation.
- Do not apply over eyes.
- If eye irritation occurs, flush with water for 5 minutes.
- Keep away from children.
- Re-use could result in risk of cross-infection and reduced performance.
- Contains Chitosan from shellfish – allergy studies show no adverse reaction.
- Data on file at Medtrade Products Ltd.

### Contraindications

- Do not use in abdominal wounds and wounds unamenable to pressure.
- Do not pack into body cavities.
- Device not intended for surgical use.



# CLINICAL SUMMARIES



## Clinical Studies

- 1 Winstanley M, Smith JE, Wright C. Catastrophic haemorrhage in military major trauma patients: a retrospective database analysis of haemostatic agents used on the battlefield. J R Army Med Corps. 2019 Dec;165(6):405-409. doi: 10.1136/jramc-2018-001031. Epub 2018 Oct 3. PMID: 30287682.

**Summary:** Retrospective database analysis of haemostatic agents used on the battlefield, drawn from the UK Joint Theatre Trauma Registry from 2003 to 2014 during combat operations in Iraq and Afghanistan. Data included patient demographics, the use of haemostatic dressings, New Injury Severity Score (NISS) and patient outcome. Of 3,792 cases, a haemostatic dressing was applied in 317 (either CELOX, HemCon or QuikClot). When comparing patients who had a haemostatic dressing applied versus no haemostatic agent, there was a 7% improvement in survival. The paper also concluded that CELOX was the only individual haemostatic dressing that was associated with a statistically significant improvement in survival.

**FOCUS: HAEMORRHAGE CONTROL; INCREASED SURVIVAL - MILITARY**

- 2 Hatamabadi HR, Asayesh Zarchi F, Kariman H, Arhami Dolatabadi A, Tabatabaey A, Amini A. CELOX-coated gauze for the treatment of civilian penetrating trauma: a randomized clinical trial. Trauma Mon. 2015 Feb;20(1):e23862. doi: 10.5812/traumamon.23862. Epub 2015 Jan 20. PMID: 25825701; PMCID: PMC4362036.

**Summary:** Randomised clinical trial using CELOX Gauze to treat civilian penetrating trauma in an Iranian hospital ER Department against a control group treated with simple pressure dressings (n= 80 in each group, 160 in total). Examined the role of CELOX in cases including stab wounds with knives and glass and motor vehicle collisions. The time for achievement of haemostasis and the amount of bleeding were recorded. Data were analysed using SPSS Version 21 and Stata 13. A P value of less than 0.05 was considered statistically significant. Haemostasis was achieved within 5 minutes in 32.5% of the control group and 51.3% of the intervention group. Using CELOX Gauze significantly reduced the time to haemostasis ( $P = 0.01$ ) and blood loss was significantly lower in the CELOX group compared to the controls ( $P < 0.05$ ). Conclusion: CELOX Gauze achieved haemostasis in penetrating limb trauma considerably faster than conventional pressure bandages.

**FOCUS: SPEED OF HAEMOSTASIS IN PENETRATING LIMB TRAUMA**



- 3 Pozza M, Millner RW. CELOX (chitosan) for haemostasis in massive traumatic bleeding: experience in Afghanistan. Eur J Emerg Med. 2011 Feb;18(1):31-3. doi: 10.1097/MEJ.0b013e32833a5ee4. PMID: 20461007.

**Summary:** Field study illustrating effectiveness of CELOX Granules in treating 21 soldiers in Afghanistan suffering with gunshot wounds, mainly in limbs: prior to CELOX Applicator availability in the field, so teams improvised using plastic syringes with the ends cut off to compact the CELOX deep inside penetrating wounds, leading to quick haemostasis with stable clots. In 18 patients, haemostasis was obtained in less than one minute, while for three patients whose arterial haemorrhage was massive, further applications were necessary. Once haemostasis had been achieved with the formation of the coagulum, compressive medication was applied. For 15 patients with wounds to the limbs, once haemostasis had been obtained, the tourniquet was removed. In all cases, the haemorrhage was controlled. No patient reported pain during or after the administering of CELOX and no changes to the tissue surrounding the injuries were noted. The CELOX was easily irrigated out after definitive treatment. Conclusion: CELOX seemed completely safe and had not shown significant side effects.

**FOCUS: RAPID HAEMOSTASIS; STABLE CLOTS; NO APPARENT SIDE EFFECTS; EASY REMOVAL AFTER TREATMENT - MILITARY**

- 4 Tan ECTH, Bleeker CP.: Field experience with a chitosan-based hemostatic dressing. MCI Forum 3(4): 11-15, 2011. (Clinical)

**Summary:** Field experience of military trauma surgeon working as part of a helicopter-based Dutch medical team. Involved three patients treated while stationed at Volkel Airbase (working alongside Dutch ambulance service) and four during deployment in Afghanistan. Injuries resulted from a severe motor accident, bomb and gunshot wounds. Indication in six patients was traumatic bleeding, and one post-surgical bleeding. After applying the chitosan gauze (described as easy to use and simple to apply), manual pressure was applied for about five minutes and then covered with an occlusive bandage. Cases were purely observational and without long-term follow-up, but the team concluded that CELOX was as easy to use as a gauze bandage and that such dressings should be available to every military nurse and medic in the chain of care - as well as carried by every soldier going into combat.

**FOCUS: HAEMOSTASIS; EASE OF APPLICATION - MILITARY / TRAUMA**

- 5** Bar J, David A, Khader T, Mulcare M, Tedeschi C. Assessing Coagulation by Rotational Thromboelastometry (ROTEM) in Rivaroxaban-Anticoagulated Blood Using Hemostatic Agents. *Prehosp Disaster Med.* 2017 Oct;32(5):580-587. doi: 10.1017/S1049023X17006641. Epub 2017 Jun 19. PMID: 28625215.

**Summary:** Analysis of human blood samples taken from eight adult patients taking the increasingly common anticoagulant Rivaroxaban and presenting at two US Emergency Departments. Using Rotational Thromboelastometry (ROTEM), study analysed Clotting Time (CT), Clot Formation Time (CFT) and Maximum Clot Firmness (MCF). Of samples treated with a chitosan-based agent, six (75.0%) showed reductions in CT, three (37.5%) showed reductions in CFT, and five (62.5%) showed increases in MCF. Study concludes that chitosan-based haemostatic agents may be effective at improving coagulation in such patients, mainly regarding CT and CTF.

**FOCUS: IMPROVED CLOTTING AND CLOT FORMATION IN PATIENTS TAKING RIVAROXABAN**

- 6** Kozen BG, Kircher SJ, Henao J, Godinez FS, Johnson AS. An alternative hemostatic dressing: comparison of CELOX, HemCon, and QuikClot. *Acad Emerg Med.* 2008 Jan;15(1):74-81. doi: 10.1111/j.1553-2712.2007.00009.x. PMID: 18211317.

**Summary:** In vivo porcine study of 48 swine (four treatment groups, 12 in each) to compare the performance of SG and combat gauze dressings, CELOX (CX), HemCon (HC) and QuikClot (QC). Each agent was applied with 5 minutes of manual pressure followed by a standard field compression dressing. CX reduced rebleeding to 0% ( $p < 0.001$ ), HC to 33% (95% CI = 19.7% to 46.3%,  $p = 0.038$ ), and QC to 8% (95% CI = 3.3% to 15.7%,  $p = 0.001$ ), compared to 83% (95% CI = 72.4% to 93.6%) for SD. CX improved survival to 100% compared to SD at 50% (95% CI = 35.9% to 64.2%,  $p = 0.018$ ). Survival for HC (67%) (95% CI = 53.7% to 80.3%) and QC (92%; 95% CI = 84.3% to 99.7%) did not differ from SD. CELOX was the only treatment to reduce rebleeding to 0% and improve survival by 100%.

**FOCUS: IMPROVED HAEMORRHAGE CONTROL; IMPROVED SURVIVAL**

## POST MARKET CLINICAL FOLLOW UP USER SURVEY REPORT

Assessment of real world performance of CELOX™ Haemostat Device CE Family by trained emergency responders in 2022

***CELOX™ Haemostat Devices achieved haemostasis after the first application in 99.3% of cases carried out by respondents including ER physicians, medics, nurses and other emergency personnel.***

***The study covered 292 cases involving single or multiple wounds ranging from cutting / piercing and blunt trauma to gunshots and RTAs – 85% of which were described as involving ‘moderate to severe bleeding’.***

***There were no adverse events for any of the products including those used to treat patients on anticoagulation therapy.***

### KEY FINDINGS

**99.3%** success rate, 290/292 cases achieved haemostasis after the first application – even those involving the most severe bleeding cases

**100%** success rate in cases using CELOX Rapid, the most used product

**100%** success rate on safety: no adverse events reported when using any of the products

**99%** of respondents across the whole study rated the CELOX™ family of Haemostat Devices ‘good’ or ‘excellent’

### Objective

The study was designed to assess safety and performance of the CELOX™ range including CELOX™ Haemostatic Granules, CELOX™-A Applicator, CELOX™ Gauze, CELOX™ Z-Fold Gauze and CELOX™ Rapid Z-Fold Gauze.

Specifically, the criteria were:

- Performance of the device on first application in stopping the bleeding (achieving haemostasis) of primary bleeding wound sites
- Safety of the device – through the collection of adverse events over the life cycle of use from application to removal.

### Methodology

Data was gathered from surveys completed by trained emergency responders who had used the devices to treat life-threatening primary bleeding in 292 cases.

Based in England, approximately 46% were physicians and 38% nurses, with 16% in other roles. A maximum of 10 survey submissions were permitted per trained emergency responder.

The majority of respondents (91%) had used three or more different classes of CELOX devices in the previous 12 months and 86% of respondents had used more than 50 CELOX devices in the previous 12 months.



## Wound type and severity

Most wounds were single (64%) and caused by cutting and blunt trauma (43%), although there were also cases of multiple wounds and other causes of injury such as firearms / ammunition, explosions, road accidents and surgery.


Injury mechanisms the CELOX devices were used for:

| INJURY MECHANISM                             | SINGLE WOUND | MULTIPLE WOUNDS | TOTAL (N) | TOTAL (%) |
|----------------------------------------------|--------------|-----------------|-----------|-----------|
| Cutting and piercing instruments and objects | 98           | 27              | 125       | 43%       |
| Blunt trauma                                 | 40           | 31              | 71        | 24%       |
| Firearm / ammunition                         | 28           | 5               | 33        | 11%       |
| Explosive                                    | 2            | 20              | 22        | 8%        |
| Road accident                                | 2            | 12              | 14        | 5%        |
| Surgery                                      | 5            | 2               | 7         | 2%        |
| Not specified                                | 20           | 0               | 20        | 7%        |

Wound depths and lengths were recorded: in terms of depth, 49% penetrated below dermis level (31% to fascia level and 18% to muscle level) and most (73%) had a length of up to 10cms. The most registered primary wound location was the lower leg (25%).

| PRIMARY WOUND LOCATIONS | N          |
|-------------------------|------------|
| Lower leg               | 119        |
| Upper leg               | 107        |
| Abdomen                 | 14         |
| Chest                   | 10         |
| Back                    | 97         |
| Head                    | 64         |
| Other                   | 73         |
| <b>Total</b>            | <b>484</b> |

Wound severity was calculated based on an NISS-score, with the majority (248 or 85%) of cases involving moderate to severe bleeding.



## Performance

In 290/292 of the cases, haemostasis of primary (life-threatening) bleeding wound sites was achieved after the first application of one of the devices – even in cases of the most severe bleeding.

**The most used product was CELOX Rapid - applied in 84 cases - followed by CELOX Gauze (76), CELOX Z-Fold (55) CELOX Granules (44) and CELOX-A (33).**

## Incorrect application

In the two cases where haemostasis was not achieved, the products were used incorrectly.

The first case involved a 5-10cm cutting / piercing injury to the patient's back, penetrating to the fascia (as well as a second lesser injury to the chest). The responder used CELOX Granules which are designed primarily for large surface wounds over which the granules can be poured: using a CELOX Gauze to pack this wound with moderate bleeding would have been more suitable.

CELOX Gauze would also have been a better product in the second case – a gunshot dermis head wound with moderate bleeding. The responder used a CELOX-A Applicator which is actually designed to treat narrow, hard to reach wounds and get to the source of bleeding.

## Safety

In terms of safety, there were no adverse events reported when using any of the products.

## CELOX™ Rapid

Respondents recorded the performance of CELOX Rapid with a 100% success rate in the cases in which it was used.

It was the most frequently used product across the whole study which recorded that it exceeded expectations in terms of time to haemostasis.

## CONCLUSION

Clinical performance of the CELOX range proves to be highly successful in addressing multiple wounds in the hands of multiple clinical personnel controlling moderate to severe bleeding. 99.3% of the survey participants said haemostasis was achieved after the first application – even in cases involving the most severe bleeding.

Every responder using CELOX Rapid said it was 100% successful, and 99% across the survey rated the CELOX family 'good' or 'excellent' with a 100% safety record; the survey conclusion is a clear endorsement of the effectiveness of CELOX in clinical practice – particularly the highly pressured and demanding environment of the Emergency Department.

For more information contact: [celoxenquiries@medtrade.co.uk](mailto:celoxenquiries@medtrade.co.uk)  
CELOX™ Medical, Medtrade Products Ltd., Electra House,  
Crewe Business Park, Crewe, Cheshire CW1 6GL, UK

**CELOX™ MEDICAL**  
[celoxmedical.com](http://celoxmedical.com)

## CELOX RAPID POST MARKET CLINICAL SURVEY REPORT

Assessment of real-world performance of CELOX™ Rapid by emergency physicians and trained emergency responders 2022

***CELOX™ Rapid achieved haemostasis after the first application in 100% of cases carried out by respondents including ER physicians, medics, nurses, and other emergency personnel.***

***This sub-analysis from a larger CELOX™ 292 study covered 84 cases involving single or multiple wounds ranging from cutting/piercing and blunt trauma to gunshots and road traffic accidents – 90% of which were described as involving ‘moderate to severe bleeding’, 21% of which were on anticoagulation therapy.***

***There were no adverse events recorded.***

### KEY FINDINGS

**100%** success rate, 84/84 cases achieved haemostasis after the first application using CELOX™ Rapid – even those involving the most severe bleeding cases

**No** adverse events reported when using CELOX™ Rapid

**All** respondents across the sub-analysis rated CELOX™ Rapid ‘good’ or ‘excellent’

### Objective

The original Post-marketing Follow-up study was designed to assess safety and performance of the CELOX™ range of Haemostat Devices. Data was gathered from surveys completed by trained emergency responders who had used CELOX™ range to treat life-threatening primary bleeding in 292 cases. The most-used product was CELOX™ Rapid (84 cases). This sub-analysis specifically focused on an assessment of CELOX™ Rapid.

Specifically, the criteria were:

- Performance of CELOX™ Rapid on first application in stopping the bleeding (achieving haemostasis) of primary bleeding wound sites

- Safety of the device – through the collection of adverse events over the life cycle of use from application to removal

### Methodology

Data was gathered from surveys completed by trained emergency responders who had used the devices to treat life-threatening primary bleeding in 84 cases from 41 responders in 41 separate locations

Based in England, approximately 44% were physicians and 42% nurses, with 14% in other roles. A maximum of 10 survey submissions were permitted per trained emergency responder.

All respondents had used two or more different classes of CELOX devices in the previous 12 months and 90% of respondents had used more than 50 CELOX devices in the previous 12 months.

## Wound type and severity

Most wounds were single (54%) and caused by cutting and blunt trauma (35% and 35%, respectively), although there were also cases of multiple wounds and other causes of injury such as firearms or ammunition (4%), explosions (14%), road accidents (5%), and surgery (2%).

Injury mechanisms the Celox devices were used for:


| INJURY MECHANISM                             | SINGLE WOUND | MULTIPLE WOUNDS | TOTAL (N) | TOTAL (%) |
|----------------------------------------------|--------------|-----------------|-----------|-----------|
| Cutting and piercing instruments and objects | 21           | 8               | 29        | 35%       |
| Blunt trauma                                 | 16           | 13              | 29        | 35%       |
| Firearm / ammunition                         | 0            | 3               | 3         | 4%        |
| Explosive                                    | 1            | 11              | 12        | 14%       |
| Road accident                                | 0            | 4               | 4         | 5%        |
| Surgery                                      | 2            | 0               | 2         | 2%        |
| Not specified                                | 5            | 0               | 5         | 6%        |

In two patient's multiple primary wound locations were identified, resulting in 87 primary wounds sites from in 84 subjects.

Wound depths and lengths were recorded. Most wounds (70%) had a length of 10 cm or less. In terms of depth, 53% of wounds were at the level of the dermis, and 47% penetrated below dermis level (30% to fascia level and 17% to muscle level). Most primary wound locations were the upper leg (29%) followed by lower leg (26%).

| PRIMARY WOUND LOCATIONS | N         |
|-------------------------|-----------|
| Lower leg               | 23        |
| Upper leg               | 25        |
| Chest                   | 0         |
| Back                    | 18        |
| Head                    | 10        |
| Other                   | 11        |
| <b>Total</b>            | <b>87</b> |

Wound severity was calculated based on an NISS-score, with the majority (90%) of cases involving moderate to severe bleeding. In 21% of cases, anticoagulation therapy was used.



## Performance

In 84/84 (100%) of the cases, haemostasis of primary (life-threatening) bleeding wound sites was achieved after the first application of one device – even in cases of the most severe bleeding.

## User experience

User experience of CELOX™ Rapid was calculated by asking respondents to rate their experience with the device on a 5-point scale, ranging from 'very poor' to 'excellent'. All ratings given were either 'good' (24%) or 'excellent' (76%).

## Safety

There were no (0%) adverse events reported when using CELOX™ Rapid.

## CONCLUSION

Clinical performance of CELOX™ Rapid proves to be highly successful in addressing multiple wounds in the hands of a wide range of clinical personnel needed for controlling moderate to severe bleeding. 100% of survey participants of this sub-analysis said haemostasis was achieved after the first application – even in the cases involving the most severe bleeding.

Every responder using CELOX™ Rapid said it was 100% successful, and 100% rated CELOX™ Rapid 'good' or 'excellent', with a 100% safety record.

The conclusion drawn from the sub-analysis strongly supports the efficacy of CELOX™ Rapid in real world clinical settings, especially in the high pressure and challenging conditions of the Emergency Department.

CELOX™ Rapid is proven to control moderate to severe bleeding even in the presence of anticoagulants.



# OUR PRODUCTS



**CEL+X™ RAPID**

**CEL+X™ GAUZE**

**CEL+X™ GRANULES**

**CEL+X™ -A**

# TECHNICAL DATA SHEET

## Product Data Sheet CELOX Rapid CE

**CELOX<sup>TM</sup> RAPID**

### DESCRIPTION

The haemostatic of choice by the UK Ministry of Defense<sup>1</sup>, CELOX Rapid is our fastest-acting haemostatic gauze that removes any delay by speeding up packing time<sup>2</sup> and reducing compression time to 60 seconds, or until bleeding stops – typically saving over two minutes of treatment time, compared to other brands.

### PRESENTATION

CE: 1.5m long x 7.6cm wide 'Z-fold' gauze.

### FEATURES

- Can work with 60 seconds compression or until bleeding stops<sup>3</sup>
- Faster packing time than other leading brands<sup>2</sup>
- Rapid action reduces blood loss<sup>4</sup>
- Stops hypothermic bleeding<sup>5</sup> as found in severe traumatic injuries

### HOW TO USE

Tightly pack to source of the bleeding, above skin level. If bleeding persists, apply a firm compression for 60 seconds or until bleeding stops.

### INDICATIONS FOR USE

To be used by trained emergency responders in the pre-hospital setting for temporary treatment of emergency life-threatening bleeding. Patient Target Group: adults and children, excluding neonates and infants.

### ORDERING INFORMATION

FG Code: FG08839021 CE / 100 packs per case

### STORAGE

CELOX products should be stored in dry conditions at ambient temperature. No special storage conditions are required or indicated on the product labelling.

Shelf life five years from date of manufacture.



|                       | CE              |
|-----------------------|-----------------|
| Packet size (approx)  | Width – 11.1cm  |
|                       | Height – 0.5cm  |
|                       | Length – 13.0cm |
|                       | Weight – 30g    |
| Shipper size (approx) | Width – 40cm    |
|                       | Height – 16cm   |
|                       | Length – 50cm   |
|                       | Weight – 3.9kg  |

For more information visit:  
**celoxmedical.com**

References: 1. CELOX. UK MoD Selects CELOX Rapid Haemostatic Gauze for all Branches of the UK Military. Cision PR Newswire, 31 Jan, 2018, 15:48 GMT. Available at: <https://prn.to/2J51zsl>. Accessed September 2019 2. Hoggarth A, et al. Reduced application time with a rapid-packing gauze haemostat. Poster presentation at ATACCC 2011, FL (In-vitro) 3. Hoggarth A, et al. Testing a new gauze hemostat with reduced treatment time. Poster presentation at ATACCC, Ft Lauderdale, August 2011. 4. Hoggarth A, et al. Mechanism of action of a rapid-acting gauze hemostat. Poster presentation at ATACCC 2011, Fort Lauderdale, FL (In-vitro) 5. Khoshmohabat H, et al. Overview of agents used for emergency hemostasis. Trauma 2016;21(1):e26023 (database search)

## How to control life-threatening bleeding with **CELOX<sup>TM</sup> RAPID**



1



**Tear open pack.** Before application identify and apply direct pressure on the main part of the bleeding then remove excess blood where practical. Take out the CELOX Rapid and take one end of Z-folded gauze.

2



**Tightly pack the unfolding CELOX Rapid** directly to the source of the bleeding. Pack remaining wound with CELOX Rapid or standard gauze above skin level.

3



**If bleeding persists** apply **FIRM** pressure directly to the wound for 1 minute or until bleeding stops.

4



**Excess CELOX Rapid** can be torn or cut if necessary. Wrap and tie with a bandage so as to maintain pressure on the wound.

5

**Dispose of any remaining CELOX Rapid** according to local standard protocols for biological waste.

6

**Transfer patient** to medical facilities as soon as possible.

7

**Show empty pack** to medical personnel.

# PRODUCT SPECIFICATIONS

## Product Specifications CELOX Rapid CE



### SHIPPER CASE

| Shipper                         | Variant 1         | Variant 2         |
|---------------------------------|-------------------|-------------------|
| Part number                     | <b>FG08839021</b> | <b>FG08839021</b> |
| Product description             | CELOX RAPID CE    | CELOX RAPID CE    |
| Height - mm                     | 190               | 160               |
| Width - mm                      | 330               | 400               |
| Length - mm                     | 400               | 500               |
| Packed shipper quantity - units | 100               | 100               |
| Packed shipper weight - kg      | 3.8               | 3.9               |

### PALLET DIMENSION

|                   | Variant 1 | Variant 2 |
|-------------------|-----------|-----------|
| Cases per layer   | 9         | 6         |
| Layers per pallet | 6         | 8         |
| Cases per pallet  | 54        | 48        |
| Total units       | 5400      | 1200      |
| Height - mm       | 1290      | 1430      |
| Width - mm        | 1200      | 1200      |
| Length - mm       | 1000      | 1000      |
| Weight - kg       | 220.0     | 220.0     |

### GTIN NUMBER CE

| Number         | Description         |
|----------------|---------------------|
| 15060206630137 | Each                |
| 75060206630139 | Shipper Case of 100 |

NCAGE: U02Y9 / NSN NUMBER: 6510991846453





## Product Data Sheet CELOX Gauze (5ft) CE

**CELOX™ GAUZE**

### DESCRIPTION

Recommended by the US Committee on Tactical Combat Casualty Care (CoTCCC)<sup>1</sup> and is used by NATO forces and first responder units around the world. CELOX Gauze is designed to stop bleeding from arterial injuries, road traffic accidents and other life-threatening injuries.

### PRESENTATION

CE: 1.5m long x 7.6cm wide 'Z-fold' gauze.

### FEATURES

- Significantly reduces blood loss<sup>2</sup>
- Stops severe traumatic bleeding
- Works independently of the body's clotting mechanism
- Stops hypothermic bleeding and increases chance of survival<sup>3</sup>
- CELOX Gauze demonstrated a statistically significant improvement in survival (7%) and most evidently in the more severely injured<sup>4</sup>

### HOW TO USE

Tightly pack to source of the bleeding, above skin level. Apply a firm compression for three minutes, or until bleeding stops.

### INDICATIONS FOR USE

To be used by trained emergency responders in the pre-hospital setting for temporary treatment of emergency life-threatening bleeding. Patient Target Group: adults and children, excluding neonates and infants.

### ORDERING INFORMATION

FG Code: 5ft Z-Fold FG08838031 CE / 100 packs per case

### STORAGE

CELOX products should be stored in dry conditions at ambient temperature. No special storage conditions are required or indicated on the product labelling.

Shelf life five years from date of manufacture.



|                       | CE              |
|-----------------------|-----------------|
| Packet size (approx)  | Width – 11.1cm  |
|                       | Height – 0.5cm  |
|                       | Length – 13.2cm |
|                       | Weight – 32g    |
| Shipper size (approx) | Width – 40cm    |
|                       | Height – 16cm   |
|                       | Length – 50cm   |
|                       | Weight – 3.9kg  |

For more information visit:  
**celoxmedical.com**

References: 1. CoTCCC Guidelines 2018. Available at: <https://deployedmedicine.com/content/40> Accessed September 2019 2. Rall JM, et al. Comparison of novel hemostatic gauzes with QuikClot Combat Gauze in a standardized swine model of uncontrolled haemorrhage. J Trauma Acute Care Surg 75(2) suppl 2 S150-S156 (2013) (In-vivo) 3. Koksai O et al. Hemostatic effect of a chitosan linear polymer (CELOX) in a severe femoral artery bleeding rat model under hypothermia or warfarin therapy. Turk J Trauma & Emerg Surg. 2011; 17:199-204 (in-vivo). 4. Winstanley M, Smith JE, Wright C. Catastrophic haemorrhage in military major trauma patients: a retrospective database analysis of haemostatic agents used on the battlefield. J R Army Med Corps 2018;0:1-5 (retrospective study)

# HOW TO GUIDE

## How to control life-threatening bleeding with **CELOX™ GAUZE**



1



**Tear open pack.** Before application identify and apply direct pressure on the main part of the bleeding then remove excess blood where practical. Take out the CELOX Z-Fold Gauze and take hold of one end with the other hand.

2



**Tightly pack the unfolding CELOX Z-Fold Gauze** directly to the source of bleeding. Pack remaining wound with CELOX Z-Fold Gauze or standard gauze above skin level. Excess CELOX Z-Fold Gauze can be torn or cut if necessary.

3



**Apply FIRM pressure** directly to the wound for 3 minutes. If bleeding persists apply additional pressure for an additional 3 minutes.

4



**Wrap and tie** with a bandage so as to maintain pressure on the wound.

5

**Dispose of any remaining CELOX Z-Fold Gauze** according to local standard protocols for biological waste.

6

**Transfer patient** to medical facilities as soon as possible.

7

**Show empty pack** to medical personnel.

# PRODUCT SPECIFICATIONS

## Product Specifications CELOX Gauze (5ft) CE



### SHIPPER CASE

| Shipper                         | Variant 1          | Variant 2          |
|---------------------------------|--------------------|--------------------|
| Part number                     | FG08838031         | FG08838031         |
| Product description             | CELOX 5ft GAUZE CE | CELOX 5ft GAUZE CE |
| Height - mm                     | 190                | 160                |
| Width - mm                      | 330                | 400                |
| Length - mm                     | 400                | 500                |
| Packed shipper quantity - units | 100                | 100                |
| Packed shipper weight - kg      | 3.8                | 3.9                |

### PALLET DIMENSION

|                   | Variant 1 | Variant 2 |
|-------------------|-----------|-----------|
| Cases per layer   | 9         | 6         |
| Layers per pallet | 6         | 8         |
| Cases per pallet  | 54        | 48        |
| Total units       | 5400      | 1200      |
| Height - mm       | 1290      | 1430      |
| Width - mm        | 1200      | 1200      |
| Length - mm       | 1000      | 1000      |
| Weight - kg       | 220.0     | 220.0     |

### GTIN NUMBER CE

| Number         | Description         |
|----------------|---------------------|
| 15060206630205 | Each                |
| 75060206630207 | Shipper Case of 100 |

NCAGE: U02Y9 / NSN NUMBER: 6510016239910



## Product Data Sheet CELOX GRANULES CE

**CELOX<sup>TM</sup> GRANULES**

### DESCRIPTION

The original CELOX product – proven to save lives and reliably stop arterial bleeding. CELOX Granules mould to the shape of the wound, even in complex shaped injuries.<sup>1</sup>

### PRESENTATION

15g / 0.5oz sachets

### FEATURES

- Significantly reduces blood loss<sup>2</sup>
- Treats irregularly shaped wounds and multiple injuries<sup>1</sup>
- Easy to use and remove<sup>3</sup>
- Successful haemostasis with the use of CELOX Granules was observed in 100% (21) of patients<sup>1</sup>
- Improve coagulation in anticoagulated blood<sup>4</sup>



### HOW TO USE

The CELOX Granules mould to the shape of the wound to get firm pressure onto the source of the bleeding, even in complex shaped injuries. Just pour granules onto the bleeding site and fill the wound. Apply a firm compression for 5 minutes, or until bleeding stops.

### INDICATIONS FOR USE

To be used by trained emergency responders in the pre-hospital setting for temporary treatment of emergency life-threatening bleeding. Patient Target Group: adults and children, excluding neonates and infants.

### ORDERING INFORMATION

FG Code: FG08830181 CE

200 packs per case

### STORAGE

CELOX products should be stored in dry conditions at ambient temperature. No special storage conditions are required or indicated on the product labelling.

Shelf life four years from date of manufacture.

23


|                       | CE              |
|-----------------------|-----------------|
| Packet size (approx)  | Width – 9.2cm   |
|                       | Height – 0.2cm  |
|                       | Length – 13.3cm |
|                       | Weight – 18g    |
| Shipper size (approx) | Width – 33cm    |
|                       | Height – 19cm   |
|                       | Length – 40cm   |
|                       | Weight – 4.6kg  |

For more information visit:  
**celoxmedical.com**

References: 1. Pozza M, Millner RW. CELOX (chitosan) for haemostasis in massive traumatic bleeding: experience in Afghanistan. Eur J Emerg Med. 2011;18(1):31–3. doi: 10.1097/2. Kozen B et al. An Alternative Hemostatic Dressing: Comparison of CELOX, HemCon and QuikClot. Acad Emerg Med. 2008; 15:74–81. (in-vivo) 3. Tan ECTH, Bleeker CP. Field experience with a chitosan-based hemostatic dressing. MCI Forum 3(4): 11-15, 2011. (Clinical) 4. Bar J, David A, Khader T, Mulcare M, Tedeschi C. Assessing coagulation by rotational thromboelastometry (ROTEM) in rivaroxaban- anticoagulated blood using hemostatic agentss. Prehosp Disaster Med. 2017;32(5):580-587.



## How to control life-threatening bleeding with **CELOX™ GRANULES**



1



**Wear gloves** (if available). Tear open CELOX packet.

2




**Before application**, identify and apply direct pressure on the main part of the bleeding then remove excess blood where practical.

3



**Immediately pour entire contents** of pouch into the wound. Fill to above skin level.

4



**Apply FIRM pressure** directly to the wound for 5 minutes using gauze. If bleeding persists or restarts apply direct pressure for an additional 5 minutes. Additional packets may be used if necessary for the wound, or other wounds requiring emergency haemostasis.

5



**Wrap and tie bandage securely** to maintain pressure on the wound (according to manufacturer's instructions).

6

**Transfer patient** to medical facilities as soon as possible.

7

**Show empty pack** to medical personnel.

8

**Dispose of any unused portion** according to local standard protocols for biological waste.


# PRODUCT SPECIFICATIONS

## Product Specifications CELOX Granules CE



### SHIPPER CASE

|                                 |              |
|---------------------------------|--------------|
| Part number                     | FG08830181   |
| Product description             | CELOX 15g CE |
| Height - mm                     | 190          |
| Width - mm                      | 330          |
| Length - mm                     | 400          |
| Packed shipper quantity - units | 200          |
| Packed shipper weight - kg      | 4.6          |



### PALLET DIMENSION

|                   |       |
|-------------------|-------|
| Cases per layer   | 9     |
| Layers per pallet | 6     |
| Cases per pallet  | 54    |
| Total units       | 10800 |
| Height - mm       | 1290  |
| Width - mm        | 1200  |
| Length - mm       | 1000  |
| Weight - kg       | 263.4 |

### GTIN NUMBER CE

| Number         | Description         |
|----------------|---------------------|
| 15060206630366 | Each                |
| 75060206630368 | Shipper Case of 200 |

NCAGE: U02Y9 / NSN NUMBER: 6505996706335



## Product Data Sheet CELOX Applicator CE

**CELOX™ -A**

### DESCRIPTION

CELOX-A is a unique applicator delivery system pre-packed with CELOX haemostatic granules and designed to get through a small entry wound, directly to the source of bleeding, in just a few seconds.

### PRESENTATION

6g (0.2oz) granules in a pre-filled applicator.

### FEATURES

- Unique high-speed applicator
- Treats narrow wounds
- Bullet, blast fragments and stab injuries
- Gets to the source of the bleeding
- Not compromised by anti-coagulant medication i.e. warfarin, heparin<sup>1</sup>
- Stops hypothermic bleeding<sup>2</sup>



### HOW TO USE

Push the applicator into the wound and expel the CELOX Granules. Fill the wound, cover and apply a firm compression for 5 minutes, or until bleeding stops.

### INDICATIONS FOR USE

To be used by trained emergency responders in the pre-hospital setting for temporary treatment of emergency life-threatening bleeding. Patient Target Group: adults and children, excluding neonates and infants.

### ORDERING INFORMATION

FG Code: FG08832021 CE / 50 packs per case

### STORAGE

CELOX products should be stored in dry conditions at ambient temperature. No special storage conditions are required or indicated on the product labelling.

Shelf life four years from date of manufacture.

|                       | CE              |
|-----------------------|-----------------|
| Packet size (approx)  | Width - 9.8cm   |
|                       | Height - 0.5cm  |
|                       | Length - 25cm   |
|                       | Weight - 32g    |
| Shipper size (approx) | Width - 21.9cm  |
|                       | Height - 23.9cm |
|                       | Length - 54cm   |
|                       | Weight - 2.3kg  |

For more information visit:  
**celoxmedical.com**

References: 1. Bar J, David A, Khader T, Mulcare M, Tedeschi C. Assessing coagulation by rotational thromboelastometry (ROTEM) in rivaroxaban-anticoagulated blood using hemostatic agents. Prehosp Disaster Med. 2017;32(5):580-587. 2. Koksai O et al. Hemostatic effect of a chitosan linear polymer (CELOX) in a severe femoral artery bleeding rat model under hypothermia or warfarin therapy. Turk J Trauma & Emerg Surg. 2011; 17:199-204

# HOW TO GUIDE

## How to control life-threatening bleeding with **CELOX™ -A**




1




**Wear gloves** (if available). Tear open CELOX-A packet, hold applicator in opened packet and remove plunger without touching the tip.

2



**While still holding applicator in the pack, remove the end cap** from the top of the applicator using the plastic tab. Insert plunger into applicator barrel containing the CELOX Granules.

3



**Remove applicator fully** from pouch using finger tabs (T-section). Grip and remove the blue plastic cap from end of applicator, just prior to use.

4



**Insert applicator** with attached plunger as far into wound as possible.

5



**Slowly push plunger in** while you withdraw the applicator from the wound. Based on wound size more than one applicator may be required.

6



**Cover the wound with gauze** to fill above skin level and apply firm pressure for five minutes.

7



**If bleeding persists** or restarts apply direct pressure for an additional 5 minutes.

Additional applicators or CELOX Haemostatic Granules may be used for the wound, or other wounds requiring emergency haemostasis.

8



**Wrap and tie bandage securely** to maintain pressure on the wound.

9

**Transfer patient** to medical facilities as soon as possible.

10

**Show empty pack** to medical personnel at facility.

11

**Dispose of used** or partially used applicator or granules according to local standard protocols for biological waste.




# PRODUCT SPECIFICATIONS

## Product Specifications CELOX Applicator CE



### SHIPPER CASE

|                                 |                          |
|---------------------------------|--------------------------|
| Part number                     | FG08832021               |
| Product description             | CELOX-A 6g Applicator CE |
| Height - mm                     | 239                      |
| Width - mm                      | 219                      |
| Length - mm                     | 540                      |
| Packed shipper quantity - units | 50                       |
| Packed shipper weight - kg      | 2.3                      |



### PALLET DIMENSION

|                   |       |
|-------------------|-------|
| Cases per layer   | 9     |
| Layers per pallet | 6     |
| Cases per pallet  | 54    |
| Total units       | 2700  |
| Height - mm       | 1345  |
| Width - mm        | 1200  |
| Length - mm       | 1000  |
| Weight - kg       | 118.5 |

### GTIN NUMBER CE

| Number         | Description        |
|----------------|--------------------|
| 15060206630144 | Each               |
| 35060206630148 | Inner case of 10   |
| 75060206630146 | Shipper case of 50 |

NCAGE: U02Y9 / NSN NUMBER: 6510995101119



# FOXSEAL™



# TECHNICAL DATA SHEET

## Product Data Sheet FOXSEAL VENTED

**FOXSEAL™ Vented**

### DESCRIPTION

FOXSEAL™ Vented is a unique 360° Hyper-Vent system and the first ever chest seal with 512 vents<sup>1</sup> giving you more ways to release pressure, prevent blockages and save a life.

### PRESENTATION

1 pack per dressing, 13.0 x 13.3cm / 5.12 x 5.24in

### FEATURES

- Sterile
- Latex-free
- Listed globally
- Fast application in any orientation
- 512 venting pathways
- Effective vent performance even if creased<sup>2</sup>
- Works on uneven or curved surfaces, under clothing or body armour<sup>2</sup>
- Solid adhesion proven in extreme conditions<sup>3</sup>
- Forms a complete seal<sup>2</sup>
- Easy grip tab enables rapid lifesaving decompression, without the need to replace the dressing

### MODE OF ACTION

Place FOXSEAL dressing centred on the wound, adhesive side down. Preferably do this while patient exhales as air pressure in the pleural cavity should be less than during inhalation. Firmly press dressing to skin around wound to seal. If another wound is present, repeat procedure with second seal. See pack for full instructions for use and any warnings.

### INDICATIONS FOR USE

FOXSEAL Vented is a temporary treatment for sucking chest wounds. For use by trained emergency responders.

### PRODUCT SAFETY INFORMATION

FOXSEAL Vented is cleared to be sold globally. Does NOT contain latex.

### STORAGE

Store at room temperature. Shelf life three years from date of manufacture.

### ORDERING INFORMATION

FG Code: FG08814541  
100 packs per case



|                       | CE             |
|-----------------------|----------------|
| Packet size (approx)  | Width - 15.5cm |
|                       | Depth - 0.2cm  |
|                       | Length - 16cm  |
|                       | Weight - 28g   |
| Shipper size (approx) | Width - 18cm   |
|                       | Depth - 18cm   |
|                       | Length - 38cm  |
|                       | Weight - 3.1kg |

For more information visit:  
**celoxmedical.com**

References: 1. A hydrogel based dressing with film roll stock and an additional Polyurethane (PU) film layer covering a central soft valve. Smart radial design consists of 3 circles, each with 8 vents. A total of 24 vents and 512 venting pathways that minimise the risk of occlusion and provide a secure one way venting system. 2. Medtrade data on file report - P7093R (2079). Vented Foxseal - Performance Bench Studies (In-vitro). 3. Medtrade data on file report - P0128RIV (2021). Testing of Adhesive Technology used in Foxseal dressings under different environmental conditions (in-vitro)



# HOW TO GUIDE

512 reasons why it'll  
never let you down

**FOXSEAL™ Vented**



FOXSEAL Vented is the first ever chest seal with 512 vents<sup>1</sup> giving you more ways to release pressure, prevent blockages and save a life.



**Wipe dirt/fluid from skin** around the wound.



**Pack has 4 tear notches**, one at each corner. Tear open pack and remove FOXSEAL Vented.




**Grip tab and peel** to remove FOXSEAL Vented from clear liner to expose the adhesive side.



**Place dressing centred** on the wound, adhesive side down.




**Firmly press** dressing to skin around wound to seal.



**Continue to assess** casualty and monitor action of chest seal.



**Use tab to vent** and re-seal if required.



**Use an additional dressing** for each additional chest wound. Additional dressing does not need to be vented, unless that is the only dressing available. A manual occlusive dressing will suffice.

For full details, instructions and warnings refer to manufacturer's instructions for use

**1. A hydrogel based dressing with film roll stock and an additional Polyurethane (PU) film layer covering a central soft valve. Smart radial design consists of 3 circles, each with 8 vents. A total of 24 vents and 512 venting pathways that minimise the risk of occlusion and provide a secure one way venting system**



## Product Data Sheet FOXSEAL CHEST SEAL

### DESCRIPTION

FOXSEAL™ Chest Seal is a pioneering occlusive dressing for the treatment of open chest wounds as a tool in prevention of pneumothorax. FOXSEAL is a compact size to fit neatly into pouches, to avoid creasing. Two seals per pack allow entry and exit wounds to be treated. Patient monitoring is vital in these injury types and the design is a simple valve free option. The chest can be vented with the easily-gripped tab and the adhesive re-seals.

### PRESENTATION

Two 13 x 13.3cm chest seal dressings are supplied in a single sterile foil pouch measuring 15.8 x 15.56in

### FEATURES

- Latex-free
- Two seals per pack
- Adhesion performance demonstrated at -18 to +55 C<sup>1</sup>
- Corrugated, high visibility peel tab for venting
- Re-sealing adhesive

### HOW TO USE

Place FOXSEAL dressing centred on the wound, adhesive side down. Preferably do this while patient exhales as air pressure in the pleural cavity should be less than during inhalation. Firmly press dressing to skin around wound to seal. If another wound is present, repeat procedure with second seal.

### INDICATIONS FOR USE

FOXSEAL is an occlusive dressing for open chest wounds. For use by trained emergency responders only. Patient Target Group: adults and children, excluding neonates and infants.

### ORDERING INFORMATION

FG Code: FG08814441

100 packs per case

### STORAGE

Store in dry conditions at room temperature. Shelf life five years from date of manufacture.



|                       | CE                        |
|-----------------------|---------------------------|
| Packet size (approx)  | Width - 15.8cm / 6.25in   |
|                       | Depth - 0.2cm / 0.08in    |
|                       | Length - 15.56cm / 6.13in |
|                       | Weight - 43g / 1.52oz     |
| Shipper size (approx) | Width - 18cm / 7.09in     |
|                       | Depth - 18cm / 7.09in     |
|                       | Length - 38cm / 14.96in   |
|                       | Weight - 4.7kg / 10.36lb  |


For more information visit:  
**celoxmedical.com**

# HOW TO GUIDE

## The dependable chest seal in a compact pack

**FOXSEAL™**

FOXSEAL Chest Seal is a pioneering occlusive dressing for the treatment of open chest wounds as a tool in prevention of pneumothorax.



**Wipe dirt/fluid from skin** around the wound.



**Pack has 4 tear notches**, one at each corner. Tear open pack and remove FOXSEAL.




**Grip tab and peel** to remove FOXSEAL from clear liner to expose the adhesive side.




**Place dressing centred** on the wound, adhesive side down.




**Firmly press** dressing to skin around wound to seal.



**Continue to assess** casualty for developing tension pneumothorax.



**Use tab to vent** and re-seal if required.



**If another wound is present**, repeat steps 1, 3, 4 & 5 with second seal.

For full details, instructions and warnings refer to manufacturer's instructions for use.

# PRODUCT SPECIFICATIONS

**FOXSEAL™ Vented**

## Product Specifications

## FOXSEAL VENTED & FOXSEAL

**FOXSEAL™**

### SHIPPER CASE

| Part number                     | FG08814541     | FG08814441         |
|---------------------------------|----------------|--------------------|
| Product description             | FOXSEAL VENTED | FOXSEAL CHEST SEAL |
| Depth                           | 18cm           | 18cm               |
| Width                           | 18cm           | 18cm               |
| Length                          | 38cm           | 38cm               |
| Packed shipper quantity - units | 100            | 100                |
| Packed shipper weight           | 3.1kg          | 4.7kg              |

### PALLET DIMENSION

| Cases per layer   | 15      | 15      |
|-------------------|---------|---------|
| Layers per pallet | 7       | 7       |
| Cases per pallet  | 105     | 105     |
| Total units       | 10500   | 10500   |
| Depth             | 141cm   | 141cm   |
| Width             | 100cm   | 100cm   |
| Length            | 120cm   | 120cm   |
| Weight            | 340.5kg | 508.5kg |

### GTIN NUMBER

| Product            | Description         | Number         |
|--------------------|---------------------|----------------|
| FOXSEAL CHEST SEAL | Each                | 15060206630694 |
|                    | Shipper case of 100 | 75060206630696 |
| FOXSEAL VENTED     | Each                | 15060206630632 |
|                    | Shipper case of 100 | 75060206630634 |

**FOXSEAL Vented - NCAGE: U02Y9 / NSN NUMBER: 6510-99-153-4041**



# REFERENCES

1. Campbell HE, et al. Quantifying the healthcare costs of treating severely bleeding major trauma patients: a national study for England. *Crit Care*. 2015;19(1):276 (Retrospective Stats)
2. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. *Lancet*. 1997;349(9064):1498-504 (Retrospective Stats)
3. World Health Organization. Injuries and violence: The facts 2010. Available at: [https://apps.who.int/iris/bitstream/handle/10665/44288/9789241599375\\_eng.PDF;jsessionid=2D221C2F8C50A0A1CD8E97A10C6A\\_A6D3?sequence=1](https://apps.who.int/iris/bitstream/handle/10665/44288/9789241599375_eng.PDF;jsessionid=2D221C2F8C50A0A1CD8E97A10C6A_A6D3?sequence=1). Accessed September 2019 (Retrospective Stats)
4. World Health Organization. Cause specific mortality and morbidity. 2009 Available at: [https://www.who.int/whosis/whostat/EN\\_WHS09\\_Table2.pdf](https://www.who.int/whosis/whostat/EN_WHS09_Table2.pdf). Accessed September 2019 (Retrospective Stats)
5. Donley ER, Loyd JW. Hemorrhage control. NCBI Bookshelf. StatPearls Publishing; 2021.
6. Sharrock AE, et al. Combat vascular injury: influence of mechanism of injury on outcome. *Injury* 2018. Doi: 10.1016/j.injury.2018.06.037 (Retrospective Stats-cohort study)
7. Rossaint R, et al. The European guideline on the management of major bleeding and coagulopathy following trauma: fourth edition. *Critical Care* 2016;20:100
8. Khoshmohabat H, et al. Overview of agents used for emergency
9. Medtrade Data on file - CSCGRG003
10. CELOX. UK MoD Selects CELOX Rapid Haemostatic Gauze for all Branches of the UK Military. Cision PR Newswire, 31 Jan, 2018, 15:48 GMT. Available at: <https://prn.to/2J51zsl>. Accessed September 2019
11. Bennett BL, Littlejohn L. Review of new topical hemostatic dressings for combat casualty care. *Mil Med* 2014; 179(5):497-514
12. Millner RWJ, et al. Chitosan arrests bleeding in major hepatic injuries with clotting dysfunction: an in vivo experimental study in a model of hepatic injury in the presence of moderate systemic heparinisation. *Ann R Coll Surg Engl* 2010; 92: 559-561. (In-vivo)
13. Iyer P, et al. Increased matrix synthesis by fibroblasts with decreased proliferation on synthetic chitosangelatin porous structures. *Biotechnol Bioeng* 2012; 109(5):1314-1325 (In-vitro)
14. Bar J, David A, Khader T, Mulcare M, Tedeschi C. Assessing coagulation by rotational thromboelastometry (ROTEM) in rivaroxaban- anticoagulated blood using hemostatic agents. *Prehosp Disaster Med*. 2017;32(5):580-587.





**CELOX™ Medical**  
Electra House, Crewe Business Park,  
Crewe CW1 6GL UK

**+44 (0)1270 500019**  
**[celoxenquiries@celoxmedical.com](mailto:celoxenquiries@celoxmedical.com)**

**[celoxmedical.com](http://celoxmedical.com)**

**CELOX™ MEDICAL**  
**MADE TO SAVE LIVES**